Supernus Pharmaceuticals (Nasdaq: SUPN) and Indivior Pharmaceuticals (Nasdaq: INDV) announced Monday they have entered into a definitive agreement to combine in a tax-free, all-stock merger of equals, creating a new company focused entirely on central nervous system disease. The combined entity will be named Supernus, Inc., trade on the Nasdaq Global Market under the ticker SUPN, and be headquartered in Rockville, Maryland.
The transaction is expected to generate pro forma net revenue of approximately $2.2 billion and pro forma adjusted EBITDA of $888 million, alongside roughly $125 million in expected annual cost synergies. Closing is targeted for the fourth quarter of 2026, subject to shareholder and regulatory approvals, and the boards of both companies have unanimously approved the deal.
How the Merger Is Structured
The deal terms reveal a genuine merger of equals rather than a straightforward acquisition. Supernus stockholders will receive 1.5401 shares of Indivior common stock for each Supernus share they hold, resulting in Indivior stockholders owning approximately 56.5% of the combined company and Supernus stockholders owning approximately 43.5%, on a fully diluted basis.
Ahead of closing, Indivior stockholders will also receive a one-time special cash dividend totaling $1.0 billion. That dividend will be funded through a combination of existing cash on hand and a $650 million term loan facility committed by Citibank. Jack Khattar, currently President and CEO of Supernus, will lead the combined company in that same role, while Tony Kingsley, currently a member of Indivior’s board, will serve as Board Chair.
Two Complementary CNS Franchises Coming Together
The strategic logic centers on scale and portfolio diversification within neuroscience. Supernus has built its business around psychiatric and neurological conditions, while Indivior has focused heavily on addiction treatment. Together, the combined company will market 11 differentiated commercial medicines spanning psychiatry, neurology, and addiction, a breadth that neither company could offer independently at this scale.
That diversification matters strategically because CNS drug development is notoriously difficult, with high clinical failure rates and long development timelines. A combined commercial portfolio spanning multiple CNS subcategories reduces the company’s dependence on any single therapeutic area or product cycle, while giving it a broader sales and marketing infrastructure to support both existing products and future pipeline candidates.
A Financially Disciplined Combination
Alongside the merger announcement, Supernus also raised its fiscal 2026 sales guidance, moving its prior range of $1.215 billion to $1.285 billion up to a new range of $1.295 billion to $1.365 billion, above the consensus estimate of $1.245 billion, a signal of underlying business strength independent of the transaction itself.
The combined company is projected to carry net debt of roughly $878 million against its earnings base, translating to a net leverage ratio below 1 times EBITDA. That conservative balance sheet is a notable feature of the deal, giving the newly formed Supernus, Inc. meaningful financial flexibility to continue investing in its internal pipeline while also pursuing additional strategic acquisitions once the merger closes.
What It Means for Investors Tracking Specialty Pharma
For investors following small and mid cap pharmaceutical companies, this deal illustrates a consolidation pattern that continues to play out across specialty therapeutic areas. Two mid-sized companies, each strong in a narrower CNS niche, are combining to build the kind of commercial scale, balance sheet strength, and portfolio diversification that increasingly determines competitive positioning in specialty pharma, without either company needing to be acquired outright by a larger strategic buyer. The broader CNS space remains one of the more active areas of biopharmaceutical development, with clinical-stage companies like NeuroSense Therapeutics continuing to advance novel approaches to neurological disease even as larger, more established players consolidate around commercial scale.
